MedWatch

Biogen files with FDA for approval of Alzheimer's therapy

Biogen has requested priority review for Alzheimer's disease therapy aducanumab, which could speed the medication's path to market.

Photo: JASON REED/REUTERS / X00458

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles